| Variable |
Survival |
Odd Ratio (95% Confidence interval) |
P-value |
| |
Alive(n= 26) |
Dead (n=14) |
|
|
| Age |
| <60 |
10 |
4 |
1.13(0.70-1.81) |
0.73 |
| ≥ 60 |
16 |
10 |
| Sex |
| Female |
7 |
3 |
0.92(0.52-1.62) |
0.76 |
| Male |
19 |
11 |
| Pathology |
| Squamous |
12 |
6 |
1.08(0.69-1.72) |
0.76 |
| Adenocarcinoma |
14 |
8 |
| Stage |
| I+II |
7 |
0 |
1.82(1.33-2.51) |
0.03 |
| III+IV |
19 |
14 |
| Performance status |
| <2 |
20 |
5 |
1.98(1.03-3.80) |
0.01 |
| ≥2 |
6 |
9 |
| Baseline CYFRA-21-1 |
| ( <5.3 vs.≥ 5.3) |
14 |
5 |
1.71(0.69-4.15) |
0.32 |
| |
12 |
9 |
| CYFRA-21 after treatment |
| (<10.4 vs. ≥ 10.4) |
19 |
0 |
3.0(1.64-5.49) |
0.001 |
| |
7 |
14 |
| Baseline CEA |
| (< 5.5 vs.≥ 5.5) |
14 |
4 |
2.14(0.81-5.67) |
0.18 |
| |
12 |
10 |
| CEA after treatment |
| ( <9.3 vs.≥ 9.3) |
20 |
1 |
3.01(1.54-5.88) |
0.001 |
| |
6 |
13 |
|
